BMY DMA
As of date:2/20/2020
BMY stock price:65.17
BMY 50 DMA:64.57
BMY 200 DMA:52.69
BMY MACD (200-50):-11.88

Also see:
BMY Market Cap History
BMY Shares Outstanding History
BMY YTD Return
BMY RSI
BMY MACD
BMY Technical Analysis

BMRC Makes Notable Cross Below Critical Moving Average
1 hour, 2 minutes ago


Notable Two Hundred Day Moving Average Cross - WTBA
1 hour, 2 minutes ago


EDIT Crosses Below Key Moving Average Level
1 hour, 2 minutes ago


Notable Two Hundred Day Moving Average Cross - ALTR
1 hour, 2 minutes ago


WDAY Crosses Below Key Moving Average Level
1 hour, 2 minutes ago


IPLDP Crosses Below Key Moving Average Level
1 hour, 2 minutes ago


Notable Two Hundred Day Moving Average Cross - BATRA
1 hour, 3 minutes ago


HLX Makes Notable Cross Below Critical Moving Average
1 hour, 34 minutes ago


Independence Holding Breaks Below 200-Day Moving Average - Notable for IHC
1 hour, 51 minutes ago


Urstadt Biddle Properties Breaks Above 200-Day Moving Average - Bullish for UBA
1 hour, 51 minutes ago


Public Service Enterprise Group Breaks Above 200-Day Moving Average - Bullish for PEG
1 hour, 56 minutes ago


Notable Two Hundred Day Moving Average Cross - MLM
1 hour, 56 minutes ago


HYS Shares Cross Below 200 DMA
1 hour, 56 minutes ago


Novo Resources (NVO.CA) Shares Cross Below 200 DMA
1 hour, 56 minutes ago


FLJP Crowded With Sellers
1 hour, 56 minutes ago


More Technical Analysis News

BMY DMABMY MACD
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the U.S., Puerto Rico and in four foreign countries. Co. has products in the following therapeutic classes: oncology; cardiovascular; and immunoscience. Co.'s products include: Opdivo; Eliquis; Orencia; Sprycel; Yervoy; Empliciti; Baraclude; the Reyataz Franchise; the Sustiva Franchise; and the Hepatitis C Franchise.

When researching a stock like Bristol-Myers Squibb, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BMY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BMY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the BMY 200 day moving average ("BMY 200 DMA"), while one of the most popular "shorter look-backs" is the BMY 50 day moving average ("BMY 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Bristol-Myers Squibb.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quotes delayed 20 minutes
Get Free SEC filing alerts for BMY:
BMY SEC Filing Email Alerts ServiceExternal link
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Bristol-Myers Squibb (BMY) is categorized under the Healthcare sector; to help you further research DMA, below are some other companies in the same sector:

BSX DMA
CAH DMA
CELG DMA
CNC DMA
COO DMA
DGX DMA
DHR DMA
DVA DMA
EW DMA
GILD DMA
More Healthcare companies »

 

BMY DMA | www.StockDMA.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in StockDMA.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.